Acceleron Pharma, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Acceleron Pharma, Inc.
In this week's podcast edition of Five Must-Know Things: the prospects for Merck’s Acceleron acquisition; the pandemic and biotech capital in-flow; an interview with Menarini’s CEO; upcoming endocrine and metabolic product disorders; and an interview with Novartis Pharma’s president.
The company announced the biggest biopharma M&A deal of the year so far, but Merck will need more large deals to manage declining sales when its top-selling product faces biosimilars in 2028.
The Cambridge, MA-based biotech has one blockbuster-tipped drug already on the market, with another in pivotal studies.
From the Aduhelm approval to exuberant stock markets, life sciences investor and In Vivo Rising Leader John Cassidy shares insights into industry trends, highlighting areas where decisions may have moved away from scientific fundamentals.
- Large Molecule